Guggenheim lowers Regeneron price target, says selloff ‘overdone’
Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Regeneron announces FDA acceptance of BLA for linvoseltamab
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
BioSpace4d
Regeneron Sues Sanofi, Alleging Stonewalling in Dupixent Pact
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
Stockhouse15d
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
THE LAWSUIT: A class action securities lawsuit was filed against Regeneron Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud ...
The Bakersfield Californian15d
Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN)– Hagens Berman
SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31 ...
ETF Daily News17d
Atomi Financial Group Inc. Buys 40 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28 ...
Insider Monkey23d
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks on Jim Cramer’s radar. Jim Cramer, host of Mad Money ...
Nasdaq25d
What to Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report
With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...
Yahoo26d
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers
(Participation is optional; you’re free to visit a partner lab without contributing to the project.) Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing ...
Fortune26d
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers
FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.
Yahoo Finance26d
UBS cuts rating on Regeneron stock amid Eylea uncertainty
Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...